Skip to the content
  • Suomeksi
  • About Us
    • > Our role
    • > BoD and management
    • > Sustainability
  • Pharma Sector
    • > Feasibilities and inquiries
    • > Research archive
    • > References for post-licensure studies
  • Newsfeed
  • Contacts
  • Suomeksi

News
31.03.2023

Why partner with FVR – Finnish Vaccine Research in studying vaccines for RSV?

clinical trials, clinical vaccine research, respiratory syncytial virus, RS-virus, RSV, vaccine trials

FVR’s unique network of ten clinical vaccine research clinics ensures good capacity and flexibility is available for conducting a successful study. ​Our expertise covers comprehensive clinical vaccine trials through phases 1-4, including register-based Real-World Evidence studies and large-scale pragmatic field trials, conducted together with healthcare providers​.

Finland offers an excellent setting for a successful study

  • educated and health-conscious people willing to participate in studies
  • generally a low drop-out rate once participants have committed to a study​
  • extensive network of research clinics
  • high quality register data and solid expertise available for phase 4 Real-World Evidence and pragmatic trials

Ilkka Seppä, ​Regional Lead Physician, explains.

Please accept the Marketing cookies to watch this video.

LOOKING FOR A CLINICAL TRIAL PARTNER?

PLEASE CONTACT info@fvr.fi FOR GENERAL INQUIRIES OR OUR BUSINESS UNIT HEADS DIRECTLY >>

  • About Us
    • Our role
    • BoD and management
    • Sustainability
  • Pharma Sector
    • Feasibilities and inquiries
    • Research archive
    • References for post-licensure studies
  • Newsfeed
  • Contacts

FVR - Finnish Vaccine Research
Peltokatu 26, 33100 Tampere, Finland
info@fvr.fi Business ID FI32566594

  • About cookies

© Copyrights 2022 FVR – Finnish Vaccine Research